CEPTAZ Drug Patent Profile
✉ Email this page to a colleague
When do Ceptaz patents expire, and when can generic versions of Ceptaz launch?
Ceptaz is a drug marketed by Glaxosmithkline and is included in one NDA.
The generic ingredient in CEPTAZ is ceftazidime. There are seventeen drug master file entries for this compound. Three suppliers are listed for this compound. Additional details are available on the ceftazidime profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Ceptaz
A generic version of CEPTAZ was approved as ceftazidime by ACS DOBFAR on November 20th, 1985.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for CEPTAZ?
- What are the global sales for CEPTAZ?
- What is Average Wholesale Price for CEPTAZ?
Summary for CEPTAZ
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 1 |
| Raw Ingredient (Bulk) Api Vendors: | 42 |
| Patent Applications: | 8,286 |
| DailyMed Link: | CEPTAZ at DailyMed |
US Patents and Regulatory Information for CEPTAZ
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Glaxosmithkline | CEPTAZ | ceftazidime | INJECTABLE;INJECTION | 050646-002 | Sep 27, 1990 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| Glaxosmithkline | CEPTAZ | ceftazidime | INJECTABLE;INJECTION | 050646-001 | Sep 27, 1990 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| Glaxosmithkline | CEPTAZ | ceftazidime | INJECTABLE;INJECTION | 050646-003 | Sep 27, 1990 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| Glaxosmithkline | CEPTAZ | ceftazidime | INJECTABLE;INJECTION | 050646-004 | Sep 27, 1990 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
